3[3]Bode B W, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes [J]. Diabetes Care, 1996,19(4): 324 ～ 327.
4[4]Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve Metabolic control, and enhance coping in adolescents with type 1 diabetes[J].Diabetes Care, 1999,22(11):1 779～ 1 784.
5[5]Herman W H, Eastman RC. The effects of treatment on the direct costs of diabetes. Diabetes[J] Care, 1998,21 (Suppl.3): 19 ～ 24.
6[6]Unger J, Fredrickson L. A primer on intensive diabetes management and insulin pumnp therapy[J]. Primayy Care Rep, 1997,3(9): 9～ 18.
二级参考文献5
1[1]Pelkonen R,KoiuistoV,Mustajoki P. Comparison of insulin regimens in the therapy of type 1 diabetes. Acta Ehdocrinol Suppl Copenh,1985,272:49-55.
2[2]Jennings Am, Lewis KS, Mundoch S, et al. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type 2 diabetic Patients poorly controlled With sulfonylureas. Diabetes Care, 1991,14:738.
3[3]Schiffens T. Quality of lift with intensive insulin therapy: a Prospective Comparison of insulin pen and Pump. Psychother Psychosom Med Psychol,1997,47(7):249-254.
4[4]Boland EA,Grey M,Oesterle A,et al. Continuous subcutaneous insulin infusion .A new way to lower risk of severe hypoglycemia , improve Metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care,1999,22(11):1 779-1 784.
5[5]Herman WH,Eastman RC .The effects of treatment on the direct costs of diabetes .Diabetes Care,1998,21 (Suppl.3):C19-24.
1IlKova H, Glaser B,Tunckale A, et al. Induction of longterm glycemic control in newly diagnosed type 2 patients by transient intensive insulin treatment [J]. Diabetes Care,1997,20(9) :1 353 -1 356.
2Castillo M, Scheen A, Lefebvre J. The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose level [ J ]. J Clin Endocrinol Metab, 1996,81 (5) : 1 975 - 1 978.
3Sivitz WI. Lipotoxicity and glucotoxicity in type 2 diabetes. Effects on development and progression [ J ]. Postagrad Med, 2001,109 ( 6 ) : 1 089- 1 094.
